Maternal characteristics and causes associated with refractory postpartum haemorrhage after vaginal birth: a secondary analysis of the WHO CHAMPION trial data.


Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
Apr 2020
Historique:
accepted: 25 11 2019
pubmed: 7 12 2019
medline: 24 3 2020
entrez: 7 12 2019
Statut: ppublish

Résumé

To assess the maternal characteristics and causes associated with refractory postpartum haemorrhage (PPH). Secondary analysis of the WHO CHAMPION trial data. Twenty-three hospitals in ten countries. Women from the CHAMPION trial who received uterotonics as first-line treatment of PPH. We assessed the association between sociodemographic, pregnancy and childbirth factors and refractory PPH, and compared the causes of PPH between women with refractory PPH and women responsive to first-line PPH treatment. Maternal characteristics; causes of PPH. Women with labour induced or augmented with uterotonics (adjusted odds ratio [aOR] 1.35; 95% CI 1.07-1.72), with episiotomy or tears requiring suturing (aOR 1.82; 95% CI 1.34-2.48) and who had babies with birthweights ≥3500 g (aOR 1.33; 95% CI 1.04-1.69) showed significantly higher odds of refractory PPH compared with the reference categories in the multivariate analysis adjusted by centre and trial arm. While atony was the sole PPH cause in 53.2% (116/218) of the women in the responsive PPH group, it accounted for only 31.5% (45/143) of the causes in the refractory PPH group. Conversely, tears were the sole cause in 12.8% (28/218) and 28% (40/143) of the responsive PPH and refractory PPH groups, respectively. Placental problems were the sole cause in 11 and 5.6% in the responsive and refractory PPH groups, respectively. Women with refractory PPH showed a different pattern of maternal characteristics and PPH causes compared with those with first-line treatment responsive PPH. Women with refractory postpartum haemorrhage are different from those with first-line treatment responsive PPH.

Identifiants

pubmed: 31808245
doi: 10.1111/1471-0528.16040
pmc: PMC7078998
doi:

Substances chimiques

Oxytocics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

628-634

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : MSD

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 World Health Organization; licensed by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

Références

Acta Obstet Gynecol Scand. 2008;87(6):652-61
pubmed: 18568465
J Gynecol Obstet Biol Reprod (Paris). 2014 Mar;43(3):244-53
pubmed: 23790963
Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):999-1012
pubmed: 18819848
Trials. 2016 Mar 17;17(1):143
pubmed: 26988231
J Gynecol Obstet Biol Reprod (Paris). 2014 Dec;43(10):936-50
pubmed: 25447386
BJOG. 2019 Dec;126(13):1612-1621
pubmed: 31410966
Clin Obstet Gynecol. 2010 Mar;53(1):147-56
pubmed: 20142652
Obstet Gynecol. 1999 Jun;93(6):1014-20
pubmed: 10362173
Lancet. 2017 May 27;389(10084):2105-2116
pubmed: 28456509
BJOG. 2020 Apr;127(5):628-634
pubmed: 31808245
N Engl J Med. 2018 Aug 23;379(8):743-752
pubmed: 29949473

Auteurs

M Widmer (M)

Department of Reproductive Health and Research, World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Geneva, Switzerland.

G Piaggio (G)

Statistika Consultoria, Campinas, Brazil.

G J Hofmeyr (GJ)

Effective Care Research Unit, Fort Hare and Walter Sisulu and Eastern Cape Department of Health, Universities of Witwatersrand, Witwatersrand, South Africa.

G Carroli (G)

Centro Rosarino de Estudios Perinatales, Rosario, Argentina.

A Coomarasamy (A)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

I Gallos (I)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

S Goudar (S)

KLE Academy of Higher Education and Research, J N Medical College, Belagavi, Karnataka, India.

A M Gülmezoglu (AM)

Department of Reproductive Health and Research, World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Geneva, Switzerland.

S L Lin (SL)

Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.

P Lumbiganon (P)

Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

K Mugerwa (K)

Department of Obstetrics and Gynaecology, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

O Owa (O)

Department of Obstetrics and Gynaecology, Mother and Child Hospital, Akure, Nigeria.

Z Qureshi (Z)

Department of Obstetrics and Gynaecology, School of Medicine, University of Nairobi, Nairobi, Kenya.

F Althabe (F)

Department of Reproductive Health and Research, World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH